The Team
Our vision – To support patients facing infertility to achieve successful treatment outcomes
Our vision – To support patients facing infertility to achieve successful treatment outcomes
Chairman of the board
Board member since: 2020
Born: 1964
Main occupation: Board professional
Shares: 30 000 direct
Options: 81 000 direct
Eva Nilsagård is currently the founder and CEO of Nilsagård Consulting AB. Eva holds an executive MBA in business management and organization as well as a master’s degree in accounting and finance from the Gothenburg School of Economics. Eva has been CFO at OptiGroup, Vitrolife and Plastal, SVP Strategy & Business development at Volvo Group and held senior positions in finance and business development at Volvo, AstraZeneca and SKF. Eva has a long experience of listed companies and over 10 years of experience as a mentor for young female managers.
Other current assignments: Chairman of the board of Diagonal Bio AB. Board member and chairman of the audit committee in Nimbus Group AB, Hansa Biopharma AB, Xbrane Biopharma AB, Aktiebolaget Svensk Exportkredit (Swedish Export Credit corporation), IRRAS AB, Addlife AB, Bufab AB, Nanexa AB, and board member of eEducation Albert AB. Nilsagård Consulting AB, Chairman of the board and CEO.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2019
Born: 1967
Main occupation: Embryologist and Unit Manager, Laboratory, Reproductive Medicine Centre, Skåne University Hospital
Shares: None
Options: None
Ingela Liljeqvist Soltić, PhD currently works as an embryologist and unit manager for laboratory and tissue establishment at the Center for Reproductive Medicine (RMC) at Skåne University Hospital. Ingela has a BSc in Biomedical Laboratory Technology from Lund University and a PhD in Biomedical Science.Ingela has previously worked as an embryologist at IVF Clinic Cura Öresund and at the pharmaceutical company Merck. Ingela has extensive experience from IVF and fertility issues.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2022
Main occupation: Senior Vice President och Global Head, Reproductive Medicine Maternal Health, RMMH, Ferring Pharmaceuticals A/S.
Shares: 0
Options: 0
Christina Östberg Lloyd innehar för närvarande en globalt ledande position på Ferring Pharmaceuticals A / S som Senior Vice President och Global Head, Reproductive Medicine Maternal Health, RMMH. Christina är M.D. och specialiserad på gynekologi och obstetrik med fokus på reproduktionsmedicin, avseende både manlig och kvinnlig infertilitet.
Other current assignments: Delägare av Care & Communication AB, Senior medicinsk rådgivare Pharmiva AB.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2020
Born: 1976
Main occupation: VP Product Development & Commercial Rx, Orifarm Healthcare
Shares: 220 132 via company
TO1: 169 132 via company
Options: 27 000 direct
Sören Melsing Frederiksen currently holds the position of Vice President, Product Development and Commercial Rx, ORIFARM GROUP A/S. Søren holds a B.A.Sc in Applied Science and a master´s degree in drug development. Previsouly, Søren held a position as VP Sales & Marketing in Galenica AB and before that held several positions within LEO Pharma and a role in Aspen Pharma Nordic. Søren has extensive experience in marketing and sales as well as the entire value chain in the pharmaceutical industry.
Other current assignments: VBM Ejendomsselskabet af 2007 Aps, board member. StenoCare A/S, board member. SML Holding ApS, board member and CEO.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2018
Born: 1991
Main occupation: CSO Spermosens AB
Shares: 1 578 240 direct
Options: None
Kushagr Punyani is founder and CSO for Spermosens AB. Kushagr holds a licentiate degree in engineering, microfluidic technology, from Lund University. From his studies in India together with Professor Sudha Srivastava, Punyani laid the foundation for Spermosens’ technology. Kushagr has also been involved in founding a number of companies that develop new technologies in medtech / pharmaceuticals.
Other current assignments: Diagonal Pharma AB, board member. Punyani Labs AB, board member. Nested Bio AB, board member.
Member of company management and major shareholder.
Z&P is a valued partner in Spermosens Development Team on the development of single-use cassettes for the rapid assessment of male fertility based on Spermosens’ IP around the direct measurement of spermatozoa within the semen, and prediction of the fusion capacity to the oocyte (egg cell).
Z&P has deep knowledge in, and experience from, the development of electrochemical biosensors, and these capabilities are being leveraged by Spermosens to deliver a product to the market, in an investment efficient manner, leveraging capital insertion with ROI.
Spermosens understanding of the fertility market, and the patent pending platform technology will supply the answer to solving problems within the IVF market. Spermosens male-fertility diagnostic products are expected to lead to fewer cycles performed to fertilisation and conception.
…we are thrilled to be selected as a trusted development partner with Spermosens and delighted to be guided by Spermosens mission . We are impressed by Spermosens break-through technology and their go-to-market strategy.
– Z&P CEO Mr. Even Zimmer
Read more at: zimmerpeacock.com
Stefan has a broad interdisciplinary background from his undergraduate studies at the nanoengineering program, and subsequent PhD studies in Physics at Lund University, Sweden. Throughout his PhD he focused on the application of nano and microstructures for the analysis of particles, for the investigation of biological samples. In addition Stefan has an extensive knowledge about miniaturization of diagnostic devices for lab-on-chip applications.
The profound technical background has been a perfect match for Spermosens, and has been an instrumental component when Stefan and his colleagues at the renowned patent law firm HØIBERG, have developed a viable IP strategy on behalf of Spermosens. The Spermosens and HØIBERG teams work closely together to maintain and develop the patent portfolio of Spermosens.
Peter Holm is a European Patent Attorney, Partner and Country Manager for Sweden at the patent law firm HØIBERG. Together with Stefan Holm Nygaard, Peter is acting as Spermosens’ strategic IP advisor. Peter has a PhDin Biochemistry and Biophysics from Karolinska Institutet, Sweden and has been working as a patent attorney at HØIBERG since 2006, assisting startup companies and individual researchers within the lifescience field, with the development of their IP strategy.
Read more at: hoiberg.com